Amryt Pharma has raised its full-year 2021 revenue guidance due to a strong performance from recent acquisition of Chiasma and its own commercial products.
Revenues are now expected in a range of US220mln - $225mln compared to previous guidance of US$210mln- $215mln.
Joe Wiley, Amryt Pharma’s chief executive, said: “Given the strong performance of our business year to date and our recent acquisition of Chiasma, we are very pleased to once again increase our full-year 2021 revenue guidance to $220-$225 million which represents growth of 20%-23% on 2020.
“This latest upward revision of guidance demonstrates our confidence in the outlook for our underlying business and our visibility is further enhanced given that we have now begun the process of integrating Chiasma into Amryt and have begun to grow our combined business.”
Shares rose 6% to 166.5p.